Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q4 FY23 results · Jan–Mar 2023
Torrent Pharmaceuticals reported revenue from operations of ₹2,491.00 crore (up 16.9% from Q4 FY22) and net profit of ₹287.00 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,491.00 | 2,131.00 | +16.9% | 2,491.00 | +0.0% |
| Other income | 9.00 | 56.00 | −83.9% | (10.00) | Turned profit |
| Total income | 2,500.00 | 2,187.00 | +14.3% | 2,481.00 | +0.8% |
| Profit before tax | 433.00 | (87.00) | Turned profit | 419.00 | +3.3% |
| Net profit for the period | 287.00 | (118.00) | Turned profit | 283.00 | +1.4% |
| EPS, basic (₹) | 8.48 | (6.98) | not comparable | 8.36 | +1.4% |
| Net margin (%) | 11.5 | -5.5 | 11.4 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,920.00 | 1,662.00 | +15.5% | 1,857.00 | +3.4% |
| Other income | 26.00 | 61.00 | −57.4% | 15.00 | +73.3% |
| Total income | 1,946.00 | 1,723.00 | +12.9% | 1,872.00 | +4.0% |
| Profit before tax | 328.00 | 345.00 | −4.9% | 353.00 | −7.1% |
| Net profit for the period | 219.00 | 221.00 | −0.9% | 229.00 | −4.4% |
| EPS, basic (₹) | 6.46 | 13.08 | not comparable | 6.78 | −4.7% |
| Net margin (%) | 11.4 | 13.3 | 12.3 |
Consolidated
- Filed with BSE
- 30 May 2023, 19:35 IST
- Board meeting
- 30 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 May 2023, 19:35 IST
- Board meeting
- 30 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE